NASDAQ:JYNT Joint (JYNT) Stock Price, News & Analysis $10.27 -0.02 (-0.19%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Joint Stock (NASDAQ:JYNT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Joint alerts:Sign Up Key Stats Today's Range$10.08▼$10.6650-Day Range$10.27▼$12.5852-Week Range$8.88▼$17.82Volume86,019 shsAverage Volume65,821 shsMarket Capitalization$153.89 millionP/E RatioN/ADividend YieldN/APrice Target$17.50Consensus RatingBuy Company OverviewThe Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.Read More… Joint Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks69th Percentile Overall ScoreJYNT MarketRank™: Joint scored higher than 69% of companies evaluated by MarketBeat, and ranked 285th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingJoint has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageJoint has only been the subject of 1 research reports in the past 90 days.Read more about Joint's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth381.82% Earnings GrowthEarnings for Joint are expected to grow by 381.82% in the coming year, from $0.11 to $0.53 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Joint is -9.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Joint is -9.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJoint has a P/B Ratio of 6.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.19% of the outstanding shares of Joint have been sold short.Short Interest Ratio / Days to CoverJoint has a short interest ratio ("days to cover") of 8.9.Change versus previous monthShort interest in Joint has recently decreased by 0.64%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldJoint does not currently pay a dividend.Dividend GrowthJoint does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.19% of the outstanding shares of Joint have been sold short.Short Interest Ratio / Days to CoverJoint has a short interest ratio ("days to cover") of 8.9.Change versus previous monthShort interest in Joint has recently decreased by 0.64%, indicating that investor sentiment is improving. News and Social Media1.4 / 5News Sentiment0.48 News SentimentJoint has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Joint this week, compared to 2 articles on an average week. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Joint insiders have not sold or bought any company stock.Percentage Held by Insiders30.20% of the stock of Joint is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.88% of the stock of Joint is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Joint's insider trading history. Receive JYNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Joint and its competitors with MarketBeat's FREE daily newsletter. Email Address JYNT Stock News HeadlinesEQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Joint Stock Company Kaspi.kz Investors – KSPIDecember 19 at 6:14 PM | businesswire.comJoint (NASDAQ:JYNT) May Have Issues Allocating Its CapitalDecember 4, 2024 | uk.finance.yahoo.comBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $125,000 by the end of his first month in office.December 21, 2024 | Weiss Ratings (Ad)Blue Bird Joint Venture Micro Bird to Establish Bus Manufacturing Facility in New York StateNovember 27, 2024 | businesswire.comThe Joint Corp. to Participate in the 13th Annual ROTH Deer Valley EventNovember 26, 2024 | globenewswire.comi-80 Gold: Still Very Attractive, Despite No Joint Venture AgreementNovember 21, 2024 | seekingalpha.comTutor Perini - O&G Joint Venture Awarded $1.18 Billion AirTrain Newark Replacement Program - Guideway and Stations ProjectNovember 18, 2024 | businesswire.comInvitation Homes Announces $200 Million Joint VentureNovember 18, 2024 | businesswire.comSee More Headlines JYNT Stock Analysis - Frequently Asked Questions How have JYNT shares performed this year? Joint's stock was trading at $9.61 at the beginning of 2024. Since then, JYNT shares have increased by 6.9% and is now trading at $10.27. View the best growth stocks for 2024 here. How were Joint's earnings last quarter? The Joint Corp. (NASDAQ:JYNT) posted its earnings results on Wednesday, September, 13th. The company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.01 by $0.02. The company had revenue of $29.31 million for the quarter, compared to analysts' expectations of $29.85 million. Joint had a negative net margin of 13.95% and a positive trailing twelve-month return on equity of 8.24%. When did Joint IPO? Joint (JYNT) raised $20 million in an initial public offering (IPO) on Tuesday, November 11th 2014. The company issued 3,000,000 shares at a price of $6.50 per share. Roth Capital Partners and Feltl and Company acted as the underwriters for the IPO and Sanders Morris Harris was co-manager. Who are Joint's major shareholders? Joint's top institutional investors include Geode Capital Management LLC (1.95%), State Street Corp (1.90%), Douglass Winthrop Advisors LLC (0.98%) and Verus Capital Partners LLC (0.89%). Insiders that own company stock include Bandera Partners Llc, Peter D Holt and Jake Singleton. View institutional ownership trends. How do I buy shares of Joint? Shares of JYNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Joint own? Based on aggregate information from My MarketBeat watchlists, some other companies that Joint investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings9/13/2023Today12/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Patent owners & lessors Sub-IndustryTrading Current SymbolNASDAQ:JYNT CUSIPN/A CIK1612630 Webwww.thejoint.com Phone(480) 245-5960Fax480-513-7989Employees444Year FoundedN/APrice Target and Rating Average Stock Price Target$17.50 High Stock Price Target$20.00 Low Stock Price Target$15.00 Potential Upside/Downside+70.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.14) Trailing P/E RatioN/A Forward P/E Ratio93.36 P/E GrowthN/ANet Income$-9,750,000.00 Net Margins-13.95% Pretax Margin-4.59% Return on Equity8.24% Return on Assets2.33% Debt Debt-to-Equity RatioN/A Current Ratio1.44 Quick Ratio1.44 Sales & Book Value Annual Sales$120.80 million Price / Sales1.27 Cash Flow$0.64 per share Price / Cash Flow16.01 Book Value$1.68 per share Price / Book6.11Miscellaneous Outstanding Shares14,984,000Free Float10,459,000Market Cap$153.89 million OptionableOptionable Beta1.57 Social Links The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report This page (NASDAQ:JYNT) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding The Joint Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Joint With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.